David Miklos

BMT specialist, Hematologist, Medical oncologist

Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
I am a physician-scientist who has established a human translational research group that fosters the development of young researchers to excel as both laboratory immunologists, and clinical translational researchers. Allogeneic hematopoietic stem cell transplantation (HSCT) can cure hematologic malignancies. In an effort to discover beneficial graft-v-tumor minor histocompatibility antigens and distinguish from detrimental graft-v-host disease(GVHD) mHA, the Miklos lab has pioneered protein microarray technologies screening for allogeneic antibodies, especially H-Y antigens following sex mismatched transplantation. Our observation that allogeneic HY antibodies develop in association with chronic GVHD has supported a series of clinical trials testing rituximab cGVHD therapy. More recently, we have applied high throughput sequencing B and T cell VDJ receptor sequences enabling: 1) lymphoid disease quantification, 2) detailed B and T cell donor reconstitution kinetics, and 3) clonal analysis of antigen specific responses following allo-HCT.

Blood and Marrow Transplant Program (BMT)

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Brigham and Women's Hospital Harvard Medical School (1998) MA

Internship: Brigham and Women's Hospital Harvard Medical School (1996) MA

Fellowship: Dana-Farber Cancer Institute (2001) MA

Medical Education: Yale University (1995) CT

B.S., University of Notre Dame (1987)

M.D., Yale University Medical School (1995)

Ph.D., Yale University, Genetics (1995)

Honors & Awards

Clinical Investigator Training Program Scholar, Harvard Medical School (2001-2003)

Medical Scientist Training Fellow, NIH (1993-1995)

Predoctoral Fellow, Howard Hughes Medical Institute (1989-1993)

Alpha Omega Alpha, Yale Medical School (1995)

Phi Betta Kappa, University of Notre Dame (1987)

Administrative Appointments

Medical Director of Stanford Cellular Therapeutics and Transplantation Laboratory, Stanford University (2011 - Present)

Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, NIH (2004 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan, A. C., Vashi, N., Faham, M., Carlton, V., Kong, K., & Miklos, D. B. (2014). Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biology of blood and marrow transplantation , 20(9), 1307-1313.

Clinical impact of H-Y alloimmunity
Popli, R., Sahaf, B., Nakasone, H., Lee, J. Y. Y., & Miklos, D. B. (2014). Clinical impact of H-Y alloimmunity. IMMUNOLOGIC RESEARCH, 58(2-3), 249-258.

Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
Logan, A. C., Zhang, B., Narasimhan, B., Carlton, V., Zheng, J., & Miklos, D. B. (2013). Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. LEUKEMIA, 27(8), 1659-1665.

A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease
Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., & Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. BLOOD, 121(24), 4955-4962.

H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease
Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., & Miklos, D. B. (2013). H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3005-3010.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
Logan, A. C., Gao, H., Wang, C., Sahaf, B., Jones, C. D., & Miklos, D. B. (2011). High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(52), 21194-21199.

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L. X., Zorn, E., & Ritz, J. (2005). Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. BLOOD, 105(7), 2973-2978.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation
Dobbelstein, C., Ahn, K. W., Haagenson, M., Hale, G. A., Van Rood, J. J., & Lee, S. J. (2013). Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(5), 741-745.

Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease
Namboodiri, A. M., Nietert, P. J., Wadia, P. P., Miklos, D. B., & Pandey, J. P. (2012). Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease. VIRAL IMMUNOLOGY, 25(4), 338-340.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.

Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL
Tseng, D., Jones, C. D., Anderson, M., Warnke, R., Zehnder, J. L., & Miklos, D. B. (2011). Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. BONE MARROW TRANSPLANTATION, 46(12), 1576-1578.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.

Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation
Porcheray, F., Miklos, D. B., Floyd, B. H., Sarantopoulos, S., Bellucci, R., & Zorn, E. (2011). Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. TRANSPLANTATION, 92(3), 359-365.

The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age
Dong, L., Wu, T., Gao, Z.-Y., Zhang, M.-J., Kan, F., & Lee, S. J. (2011). The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(8), 1205-1213.

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies
Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., & Engleman, E. G. (2011). B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. NATURE MEDICINE, 17(5), 610-U134.

Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease
Butte, A. J., Sigdel, T. K., Wadia, P. P., Miklos, D. B., & Sarwal, M. M. (2011). Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease. MOLECULAR & CELLULAR PROTEOMICS, 10(3).

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.

Recombinant antigen microarrays for serum/plasma antibody detection.
Wadia, P. P., Sahaf, B., & Miklos, D. B. (2011). Recombinant antigen microarrays for serum/plasma antibody detection. Methods in molecular biology (Clifton, N.J.), 723, 81-104.

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors
Shaw, P. J., Kan, F., Ahn, K. W., Spellman, S. R., Aljurf, M., & Pulsipher, M. A. (2010). Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. BLOOD, 116(19), 4007-4015.

H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births
Nielsen, H. S., Wu, F., Aghai, Z., Steffensen, R., van Halteren, A. G., & Goulmy, E. (2010). H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births. HUMAN REPRODUCTION, 25(11), 2745-2752.

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637-639.

Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.
Müller, A. Ms., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721-14726.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements
Boyd, S. D., Gaeta, B. A., Jackson, K. J., Fire, A. Z., Marshall, E. L., & Collins, A. M. (2010). Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements. JOURNAL OF IMMUNOLOGY, 184(12), 6986-6992.

Rituximab in hematopoietic cell transplantation
Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971-982.

Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation
Wadia, P. P., Coram, M., Armstrong, R. J., Mindrinos, M., Butte, A. J., & Miklos, D. B. (2010). Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. BLOOD, 115(10), 2077-2087.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures
Li, L., Wadia, P., Chen, R., Kambham, N., Naesens, M., & Butte, A. J. (2009). Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(11), 4148-4153.

B Cells and Transplantation: An Educational Resource
Small, T. N., Robinson, W. H., & Miklos, D. B. (2009). B Cells and Transplantation: An Educational Resource. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(1), 104-113.

H-Y antibody development associates with acute rejection in female patients with male kidney transplants
Tan, J. C., Wadia, P. P., Coram, M., Grumet, F. C., Kambham, N., & Miklos, D. B. (2008). H-Y antibody development associates with acute rejection in female patients with male kidney transplants. TRANSPLANTATION, 86(1), 75-81.

Renal pathology in hematopoietic cell transplantation recipients
Troxell, M. L., Pilapil, M., Miklos, D. B., Higgins, J. P., & Kambham, N. (2008). Renal pathology in hematopoietic cell transplantation recipients. MODERN PATHOLOGY, 21(4), 396-406.

Rituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., & Alyea, E. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. BLOOD, 108(2), 756-762.

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report
Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., & Pavletic, S. Z. (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(2), 126-137.

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
Miklos, D. B., Kim, H. T., Zorn, E., Hochberg, E. P., Guo, L. X., & Ritz, J. (2004). Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. BLOOD, 103(1), 353-359.